International Consensus on drug allergy.
Allergy. 69: 420-437Cernadas J.R. Brockow K. Romano A. et al.General considerations on rapid desensitization for drug hypersensitivity - a consensus statement.
Allergy. 65: 1357-1366Joint Task Force on Practice P, American Academy of Allergy A, Immunology, et alDrug allergy: an updated practice parameter.
Ann Allergy Asthma Immunol. 105: 259-273Shalit M. Levi-Schaffer F.Challenge of mast cells with increasing amounts of antigen induces desensitization.
Clin Exp Allergy. 25: 896-902Castells M.C. Tennant N.M. Sloane D.E. et al.Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
J Allergy Clin Immunol. 122: 574-580Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations.
Front Immunol. 8: 1472Diaferio L. Giovannini M. Clark E. et al.Protocols for drug allergy desensitization in children.
Expert Rev Clin Immunol. 16: 91-100Isabwe G.A.C. Garcia Neuer M. de Las Vecillas Sanchez L. et al.Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes.
J Allergy Clin Immunol. 142: 159-170.e2Castells M. Sancho-Serra Mdel C. Simarro M.Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization.
Cancer Immunol Immunother. 61: 1575-1584Current knowledge and management of hypersensitivity reactions to monoclonal antibodies.
J Allergy Clin Immunol Pract. 5: 600-609Mast cells and anaphylaxis.
Curr Allergy Asthma Rep. 16: 20McNeil B.D. Pundir P. Meeker S. et al.Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.
Nature. 519: 237-241Porebski G. Kwiecien K. Pawica M. et al.Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in drug hypersensitivity reactions.
Front Immunol. 9: 3027MRGPRX2 and adverse drug reactions.
Front Immunol. 12: 676354Desensitization for allergic reactions to chemotherapy.
Yonsei Med J. 60: 119-125Guilarte M. Sala-Cunill A. Luengo O. et al.The mast cell, contact, and coagulation system connection in anaphylaxis.
Front Immunol. 8: 846Doessegger L. Banholzer M.L.Clinical development methodology for infusion-related reactions with monoclonal antibodies.
Clin Transl Immunol. 4: e39Jakubovic B.D. Sanchez-Sanchez S. Hamadi S. et al.Interleukin-6: A novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association.
Allergy. https://doi.org/10.1111/all.14644Kruger-Krasagakes S. Moller A. Kolde G. et al.Production of interleukin-6 by human mast cells and basophilic cells.
J Invest Dermatol. 106: 75-79Cytokines and fever. Mechanisms and sites of action.
Ann N Y Acad Sci. 856: 83-89Lee D.W. Gardner R. Porter D.L. et al.Current concepts in the diagnosis and management of cytokine release syndrome.
Blood. 124: 188-195Silver J. Garcia-Neuer M. Lynch D.M. et al.Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin.
J Allergy Clin Immunol Pract. 8: 1668-1680.e2O'Meara S. Nanda K.S. Moss A.C.Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Inflamm Bowel Dis. 20: 1-6Bavbek S. Ataman S. Akinci A. et al.Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients.
J Allergy Clin Immunol Pract. 3: 629-632IgE-dependent signaling as a therapeutic target for allergies.
Trends Pharmacol Sci. 33: 502-509Metcalfe D.D. Peavy R.D. Gilfillan A.M.Mechanisms of mast cell signaling in anaphylaxis.
J Allergy Clin Immunol. 124 (): 639-646Liu A. Fanning L. Chong H. et al.Desensitization regimens for drug allergy: state of the art in the 21st century.
Clin Exp Allergy. 41: 1679-1689Oka T. Rios E.J. Tsai M. et al.Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells.
J Allergy Clin Immunol. 132: 922-932.e1-16Sancho-Serra Mdel C. Simarro M. Castells M.Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization.
Eur J Immunol. 41: 1004-1013de Las Vecillas Sanchez L. Alenazy L.A. Garcia-Neuer M. et al.Drug hypersensitivity and desensitizations: mechanisms and new approaches.
Int J Mol Sci. 18https://doi.org/10.3390/ijms18061316Morales A.R. Shah N. Castells M.Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen.
Ann Allergy Asthma Immunol. 94: 575-580Ang W.X. Church A.M. Kulis M. et al.Mast cell desensitization inhibits calcium flux and aberrantly remodels actin.
J Clin Invest. 126: 4103-4118Castells M.C. Wu X. Arm J.P. et al.Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49.
J Biol Chem. 269: 8393-8401Bulfone-Paus S. Nilsson G. Draber P. et al.Positive and negative signals in mast cell activation.
Trends Immunol. 38: 657-667Inhibition of anaphylactic inflammation by the gp49B1 receptor on mast cells.
Mol Immunol. 38: 1301-1305Fujioka Y. Matozaki T. Noguchi T. et al.A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion.
Mol Cell Biol. 16: 6887-6899Huber M. Helgason C.D. Damen J.E. et al.The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation.
Proc Natl Acad Sci U S A. 95: 11330-11335Katz H.R. Vivier E. Castells M.C. et al.Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high-affinity Fc receptor for IgE.
Proc Natl Acad Sci U S A. 93: 10809-10814McCormick M.J. Castells M.C. Austen K.F. et al.The gp49A gene has extensive sequence conservation with the gp49B gene and provides gp49A protein, a unique member of a large family of activating and inhibitory receptors of the immunoglobulin superfamily.
Immunogenetics. 50: 286-294Castells M.C. Klickstein L.B. Hassani K. et al.gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation.
Nat Immunol. 2: 436-442Caiado J. Bras R. Paulino M. et al.Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: Outcomes and risk factors.
Ann Allergy Asthma Immunol. 125: 325-333.e1Centers for Disease C, PreventionVital signs: health insurance coverage and health care utilization --- United States, 2006--2009 and January-March 2010.
MMWR Morb Mortal Wkly Rep. 59: 1448-1454Ramsey S.D. Martins R.G. Blough D.K. et al.Second-line and third-line chemotherapy for lung cancer: use and cost.
Am J Manag Care. 14: 297-306Sloane D. Govindarajulu U. Harrow-Mortelliti J. et al.Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies.
J Allergy Clin Immunol Pract. 4: 497-504Bonamichi-Santos R. Castells M.Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies.
Clin Rev Allergy Immunol. 54: 375-385Rituximab hypersensitivity and desensitization: a personalized approach to treat cancer and connective tissue diseases.
Ann Allergy Asthma Immunol. 123: 11-15Diagnosis and treatment of drug hypersensitivity reactions to biologicals: medical algorithm.
Allergy. https://doi.org/10.1111/all.14432Koch C. Hjelt K. Pedersen S.S. et al.Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses.
Rev Infect Dis. 13: S608-S611Burrows J.A. Nissen L.M. Kirkpatrick C.M. et al.Beta-lactam allergy in adults with cystic fibrosis.
J Cyst Fibros. 6: 297-303Legere 3rd, H.J. Palis R.I. Rodriguez Bouza T. et al.A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity.
J Cyst Fibros. 8: 418-424Foer D. Marquis K. Romero N. et al.Challenges and safety of beta-lactam desensitization during extracorporeal membrane oxygenation.
Ann Allergy Asthma Immunol. 122: 661-663Differential diagnosis of severe cutaneous drug eruptions.
Am J Clin Dermatol. 4: 561-572Pirmohamed M. Friedmann P.S. Molokhia M. et al.Phenotype standardization for immune-mediated drug-induced skin injury.
Clin Pharmacol Ther. 89: 896-901Mezzano V. Giavina-Bianchi P. Picard M. et al.Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.
BioDrugs. 28: 133-144Kitazawa T. Seo K. Yoshino Y. et al.Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
J Infect Chemother. 25: 351-354Yoshizawa S. Yasuoka A. Kikuchi Y. et al.A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S.
Ann Allergy Asthma Immunol. 85: 241-244Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ.
Clin Infect Dis. 20: 849-853Absar N. Daneshvar H. Beall G.Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients.
J Allergy Clin Immunol. 93: 1001-1005Pyle R.C. Butterfield J.H. Volcheck G.W. et al.Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction.
J Allergy Clin Immunol Pract. 2: 52-58Clinical features and severity grading of anaphylaxis.
J Allergy Clin Immunol. 114: 371-376Picard M. Pur L. Caiado J. et al.Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions.
J Allergy Clin Immunol. 137: 1154-1164.e2Brockow K. Romano A. Blanca M. et al.General considerations for skin test procedures in the diagnosis of drug hypersensitivity.
Allergy. 57: 45-51Brennan P.J. Rodriguez Bouza T. Hsu F.I. et al.Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
J Allergy Clin Immunol. 124: 1259-1266Presentation and diagnosis of hypersensitivity to platinum drugs.
Curr Allergy Asthma Rep. 15: 15Caiado J. Venemalm L. Pereira-Santos M.C. et al.Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy.
J Allergy Clin Immunol Pract. 1: 494-500Giavina-Bianchi P. Galvao V.R. Picard M. et al.Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy.
J Allergy Clin Immunol Pract. 5: 728-736Deak P.E. Kim B. Adnan A. et al.Nanoallergen platform for detection of platin drug allergies.
J Allergy Clin Immunol. 143: 1957-1960.e12Wolfson A.R. Huebner E.M. Blumenthal K.G.Acute care beta-lactam allergy pathways: approaches and outcomes.
Ann Allergy Asthma Immunol. 123: 16-34Hsu Blatman K.S. Castells M.C.Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes.
Curr Allergy Asthma Rep. 14: 453Hereditary alpha tryptasemia: genotyping and associated clinical features.
Immunol Allergy Clin North Am. 38: 483-495Chung C.H. Mirakhur B. Chan E. et al.Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
N Engl J Med. 358: 1109-1117Halpern N.A. Pastores S.M.Critical care medicine beds, use, occupancy, and costs in the United States: a methodological review.
Crit Care Med. 43: 2452-2459Breslow R.G. Caiado J. Castells M.C.Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization.
Ann Allergy Asthma Immunol. 102: 155-160
留言 (0)